Drug Trial Radar · NCT04801420
Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
625
Actual
Start
Mar 8, 2021
Primary completion
Mar 25, 2022
Study completion Jul 2, 2025
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Valneva Austria GmbH
- First posted
- Mar 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
VLA15-221 is a Phase 2 study, which will be conducted in two parts: Main Study Phase (Part A) and Booster Phase (Part B). The study will compare the safety and immunogenicity of two different primary immunization schedules applying three (Month 0-2-6) or two (Month 0- 6) vaccinations. Within the study, 600 healthy subjects aged 5-65 years will be included. Subjects with a history of Lyme borreliosis (previous infection with Borrelia) as well as Borrelia naïve subjects will be enrolled. Study duration per subject will be a maximum of 50 months per subject.
Conditions
- Lyme Borreliosis
Interventions
VLA15Biological
a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
PlaceboBiological
PBS (Phosphate Buffered Saline)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Solicited Local and Solicited Systemic Adverse Events (AEs) Within 7 Days After Vaccination 1Time frame: From Day 1 to Day 7 after vaccination 1 at Month 0
- Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 2Time frame: From Day 1 to Day 7 after vaccination 2 at Month 2
- Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 3Time frame: From Day 1 to Day 7 after vaccination 3 at Month 6
- Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Any Vaccination During the Main Study PhaseTime frame: From Day 1 to Day 7 after any vaccination 1, 2 or 3 at Month 0, 2 and 6, respectively
- Geometric Mean Titers (GMTs) for Immunoglobulin G (IgG) Against Each Outer Surface Protein A (OspA) Serotype (ST1 to ST6) at Day 208 During the Main Study PhaseTime frame: At Day 208 (Month 7)
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
New England Research Associates
Bridgeport, Connecticut
Stamford Therapeutics Consortium
Stamford, Connecticut
Chase Medical Research, LLC
Waterbury, Connecticut
Pediatric Associates of Conn. PC
Waterbury, Connecticut
Clinical Research Institute, Inc.
Minneapolis, Minnesota
Foundation Pediatrics
East Orange, New Jersey
Med Clinical Research Partners, LLC
Irvington, New Jersey
Meridian Clinical Research LLC
Binghamton, New York
Rochester Clinical Research, Inc.
Rochester, New York
Richmond Behavioral Associates
Staten Island, New York
Advantage Clinical Trials
The Bronx, New York
Velocity Clinical Research, Inc.
Cleveland, Ohio
Allegheny Health and Wellness Pavilion
Erie, Pennsylvania
Liberty Family Practice
Erie, Pennsylvania
Lockman & Lubell Pediatric Associates
Fort Washington, Pennsylvania
Hasbro Children's Hospital
Providence, Rhode Island
Rhode Island Hospital
Providence, Rhode Island
The Miriam Hospital
Providence, Rhode Island
Velocity Clinical Research Providence
Warwick, Rhode Island
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.